Skip to main content
Premium Trial:

Request an Annual Quote

Cuts at AstraZeneca

AstraZeneca announced that it will be eliminating 7,300 jobs, reports The Wall Street Journal. The Journal adds that these cuts, which are to be made by the end of 2014, will bring the company's total jobs cuts during the past five years to about 30,000. This round includes 2,200 cuts to R&D, 1,350 to manufacturing and operations, and 3,750 to administration and sales, and the closure of two neuroscience labs, one in Sweden and the other in Montreal. "AstraZeneca is ripping up some of its research roots in Europe and North America and forging more virtual research alliances with academic institutions and small biotech companies," the Journal notes.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.